Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients

Wim Adriaensen, Thomas P C Dorlo, Guido Vanham, Luc Kestens, Paul M Kaye, Johan van Griensven

Research output: Contribution to journalA1: Web of Science-articlepeer-review

14 Downloads (Pure)


Patients with visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection experience increased drug toxicity and treatment failure rates compared to VL patients, with more frequent VL relapse and death. In the era of VL elimination strategies, HIV coinfection is progressively becoming a key challenge, because HIV-coinfected patients respond poorly to conventional VL treatment and play an important role in parasite transmission. With limited chemotherapeutic options and a paucity of novel anti-parasitic drugs, new interventions that target host immunity may offer an effective alternative. In this review, we first summarize current views on how VL immunopathology is significantly affected by HIV coinfection. We then review current clinical and promising preclinical immunomodulatory interventions in the field of VL and discuss how these may operate in the context of a concurrent HIV infection. Caveats are formulated as these interventions may unpredictably impact the delicate balance between boosting of beneficial VL-specific responses and deleterious immune activation/hyperinflammation, activation of latent provirus or increased HIV-susceptibility of target cells. Evidence is lacking to prioritize a target molecule and a more detailed account of the immunological status induced by the coinfection as well as surrogate markers of cure and protection are still required. We do, however, argue that virologically suppressed VL patients with a recovered immune system, in whom effective antiretroviral therapy alone is not able to restore protective immunity, can be considered a relevant target group for an immunomodulatory intervention. Finally, we provide perspectives on the translation of novel theories on synergistic immune cell cross-talk into an effective treatment strategy for VL-HIV-coinfected patients.

Original languageEnglish
Article number1943
JournalFrontiers in Immunology
Publication statusPublished - 2018


Dive into the research topics of 'Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients'. Together they form a unique fingerprint.

Cite this